IDEMIA
1.10.2020 11:59:07 CEST | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, today announces its GREENPAY launch, an eco-friendly global offer for financial institutions, in line with its CSR* and sustainability strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005547/en/
Environmental concerns underpin IDEMIA’s business practices. Through GREENPAY, IDEMIA commits to move away from today’s “take-make-waste” attitude to redesign our habits. IDEMIA is proud to develop solutions generating less plastic and paper waste, reducing land and water pollution while also minimizing its carbon footprint.
GREENPAY is IDEMIA’s commitment to continuously improve each part of the payment card value chain, seeking to:
- Minimize the environmental impact of its processes and services
- Develop innovative, eco-friendly products, services and solutions
- Help customers achieve their environmental goals with IDEMIA’s product offering.
GREENPAY encompasses eco-friendly card body solutions, advanced card related services like eco-designed packaging, on-demand printing of PEFC/FSC certified card carrier, digital alert and e-documents among other services that enable financial institutions to deploy their sustainability transformation.
Over the last few months, IDEMIA’s customers around the world, including Latin America, the US, Europe and Asia, have adopted GREENPAY. For example:
- The RHB 1 Visa WWF Debit Card-i is a recycled PVC payment card which will be available to all new and existing RHB customers in Malaysia from July 2020. The cards contain state-of-the-art technology for seamless payments, have passed all durability tests and are ISO-certified and EMV compliant.
- IDEMIA’s trusted solutions were chosen to accompany BBVA ’s2 customers in the environmental transition journey. This partnership will progressively allow the bank to deliver cards made of “eco friendly” materials to customers in all countries where it has a presence by the end of 2021.
- IDEMIA also offers Treezor 3 , a low-natural-resource-consuming card which does not compromise on security or end-user convenience. The collaboration between IDEMIA and Treezor - French banking-as-a-service market leader - has culminated in the launch of the first ever eco-friendly card by a FinTech in France.
- IDEMIA was also awarded the “Environmental Claim Validation Summary” certification by its recycled PVC supplier “UL Environment Inc.”
Furthermore all GREENPAY products & services – through IDEMIA’s certified partner – financially contribute to key environmental projects around the world in line with the Sustainable Development Goals set up by the United Nations.
IDEMIA’s Executive VP Financial Institutions Amanda Gourbault said: “We at IDEMIA take sustainable development very seriously and believe the financial community is perfectly placed to promote green initiatives and build a better tomorrow. This is GREENPAY’s primary objective, combining all our expertise in technologies which further CSR goals.”
*CSR: Corporate Social Responsibility
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1
See PR - https://www.idemia.com/press-release/idemia-partners-rhb-bank-launch-first-recycled-debit-card-asia-pacific-2020-06-15
2
See PR - https://www.idemia.com/press-release/idemia-and-bbva-partner-launch-spains-first-payment-card-made-recycled-pvc-2020-06-05
3
See PR - https://www.idemia.com/press-release/idemia-and-treezor-launch-first-eco-friendly-payment-card-onlyone-french-fintech-firm-2020-06-26
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005547/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
